JP2012505836A5 - - Google Patents

Download PDF

Info

Publication number
JP2012505836A5
JP2012505836A5 JP2011531305A JP2011531305A JP2012505836A5 JP 2012505836 A5 JP2012505836 A5 JP 2012505836A5 JP 2011531305 A JP2011531305 A JP 2011531305A JP 2011531305 A JP2011531305 A JP 2011531305A JP 2012505836 A5 JP2012505836 A5 JP 2012505836A5
Authority
JP
Japan
Prior art keywords
amino
benzofuran
oxadiazol
diol
propane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011531305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505836A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2009/001371 external-priority patent/WO2010043000A1/en
Publication of JP2012505836A publication Critical patent/JP2012505836A/ja
Publication of JP2012505836A5 publication Critical patent/JP2012505836A5/ja
Pending legal-status Critical Current

Links

JP2011531305A 2008-10-17 2009-10-19 Ｓ１ｐ受容体モジュレーターおよびそれらの使用 Pending JP2012505836A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2008905369A AU2008905369A0 (en) 2008-10-17 S1P Receptors Modulators and Their use Thereof
AU2008905369 2008-10-17
AU2009903644 2009-08-05
AU2009903644A AU2009903644A0 (en) 2009-08-05 S1P Receptors Modulators and their use Thereof
PCT/AU2009/001371 WO2010043000A1 (en) 2008-10-17 2009-10-19 S1p receptors modulators and their use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014192502A Division JP5963823B2 (ja) 2008-10-17 2014-09-22 Ｓ１ｐ受容体モジュレーターおよびそれらの使用

Publications (2)

Publication Number Publication Date
JP2012505836A JP2012505836A (ja) 2012-03-08
JP2012505836A5 true JP2012505836A5 (enExample) 2013-02-07

Family

ID=42106136

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011531305A Pending JP2012505836A (ja) 2008-10-17 2009-10-19 Ｓ１ｐ受容体モジュレーターおよびそれらの使用
JP2014192502A Expired - Fee Related JP5963823B2 (ja) 2008-10-17 2014-09-22 Ｓ１ｐ受容体モジュレーターおよびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014192502A Expired - Fee Related JP5963823B2 (ja) 2008-10-17 2014-09-22 Ｓ１ｐ受容体モジュレーターおよびそれらの使用

Country Status (9)

Country Link
US (3) US8592399B2 (enExample)
EP (1) EP2344484B1 (enExample)
JP (2) JP2012505836A (enExample)
CN (1) CN102186845B (enExample)
AU (1) AU2009304598B2 (enExample)
CA (1) CA2740484C (enExample)
ES (1) ES2590904T3 (enExample)
NZ (1) NZ592748A (enExample)
WO (1) WO2010043000A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186845B (zh) 2008-10-17 2016-09-07 阿卡制药有限公司 S1p受体调节剂以及它们的用途
CA2739901A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
AU2010213794A1 (en) * 2009-02-10 2011-09-01 Abbott Laboratories Agonists and antagonists of the S1P5 receptor, and methods of uses thereof
KR101956129B1 (ko) * 2010-11-30 2019-03-12 아데쏘 어드밴스드 머트리얼스 우후 컴퍼니 리미티드 신규한 재생 에폭시 수지용 물질
EP2697195A1 (en) * 2011-04-14 2014-02-19 Allergan, Inc. Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
CN102993027B (zh) * 2011-09-08 2014-08-13 中化蓝天集团有限公司 4-氟-n-异丙基苯胺的定向单烷基化制备方法
AU2012354695B2 (en) 2011-12-23 2016-11-03 Meiji Seika Pharma Co., Ltd. Novel S1P receptor modulator
US9376409B2 (en) 2012-05-09 2016-06-28 Boehringer Ingelheim International Gmbh Methods for making oxetan-3-ylmethanamines
BR112015001613B1 (pt) 2012-07-27 2021-02-23 Biogen Ma Inc compostos que são agentes de modulação de s1p e/ou agentes de modulação de atx, seus usos e composição farmacêutica
US8859598B2 (en) 2012-10-04 2014-10-14 Allergan, Inc. 1, 2, 4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators
WO2014063199A1 (en) * 2012-10-26 2014-05-01 Akaal Pharma Pty Ltd Organic compounds
EP2917214B1 (en) 2012-11-07 2019-08-28 Nerviano Medical Sciences S.r.l. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
US8735433B1 (en) 2012-11-14 2014-05-27 Allergan, Inc. Aryl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators
CN103304503B (zh) * 2013-06-02 2015-03-04 张远强 抗糖尿病化合物、其制备方法和用途
CN103304499B (zh) * 2013-06-02 2015-03-04 张远强 抗糖尿病化合物、其制备方法和用途
WO2015023839A1 (en) * 2013-08-15 2015-02-19 Allergan, Inc. Aryl azetidine derivatives as sphingosine-1 phosphate receptors modulators
JPWO2015129859A1 (ja) * 2014-02-28 2017-03-30 キッセイ薬品工業株式会社 新規なアニリン誘導体、それを含有する医薬組成物およびそれらの用途
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
US20180228778A1 (en) * 2015-08-11 2018-08-16 Akaal Pharma Pty Ltd Compositions comprising s1p receptor modulators
AU2017218889A1 (en) 2016-02-09 2018-08-30 Pharmakea, Inc. Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
JP7273722B2 (ja) 2016-12-20 2023-05-15 オリゴメリックス インコーポレイテッド タウオリゴマーの形成を阻害する新規ベンゾフラン、ベンゾチオフェン及びインドール類似体並びにそれらの使用方法
JP7273723B2 (ja) 2016-12-20 2023-05-15 オリゴメリックス インコーポレイテッド タウオリゴマーの形成を阻害する新規キナゾリノン及びその使用方法
CN110831593A (zh) 2017-06-14 2020-02-21 特维娜有限公司 用于调节s1p1活性的化合物及其使用方法
KR102017324B1 (ko) * 2018-04-30 2019-09-02 경북대학교 산학협력단 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도
WO2020077014A1 (en) 2018-10-09 2020-04-16 Duke University Compositions and methods for adjuvant cancer therapeutics
TWI838437B (zh) * 2018-12-06 2024-04-11 大陸商上海濟煜醫藥科技有限公司 作為免疫調節劑的化合物及其製備方法和應用
CN109824685B (zh) * 2019-04-03 2021-03-23 辽宁中医药大学 马齿苋中化合物oleracone G及其提取分离方法与应用
BR112022003959A2 (pt) * 2019-09-05 2022-05-24 Trevena Inc Métodos para tratamento de epilepsia
MX2022005766A (es) 2019-11-19 2022-08-08 Trevena Inc Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1).
AU2021228371A1 (en) * 2020-02-28 2022-10-13 Akaal Pharma Pty Ltd S1P receptor modulators
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
TW202430514A (zh) 2022-09-30 2024-08-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
TW202430031A (zh) 2022-09-30 2024-08-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
JP2025539452A (ja) 2022-11-30 2025-12-05 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺微生物テトラヒドロイソキノリン誘導体
WO2025114167A1 (en) 2023-11-28 2025-06-05 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025191053A1 (en) 2024-03-14 2025-09-18 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025210096A1 (en) 2024-04-03 2025-10-09 Syngenta Crop Protection Ag Fungicidal compositions
WO2025210095A1 (en) 2024-04-03 2025-10-09 Syngenta Crop Protection Ag Microbiocidal tetrahydroisoquinoline compounds
CN118878551B (zh) * 2024-07-08 2026-04-28 安徽大学 一种4-溴噻吩并[2,3-c]吡啶-2-羧酸乙酯的制备方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2550646A (en) 1947-08-21 1951-04-24 Commercial Solvents Corp Polyamino alcohols and method for preparing them
DK0513387T3 (da) * 1990-11-30 2000-06-05 Otsuka Pharma Co Ltd Thiazolderivater som inhibitorer af aktivt oxygen
AU674613B2 (en) * 1993-09-28 1997-01-02 Otsuka Pharmaceutical Co., Ltd. Quinoxaline derivative as antidiabetic agent
FR2719044B1 (fr) * 1994-04-26 1996-05-31 Cird Galderma Nouveaux composés bi-aromatiques acétylénés à groupement adamantyle, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
US5883106A (en) * 1994-10-18 1999-03-16 Pfizer Inc. 5-lipoxygenase inhibitors
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US6221865B1 (en) 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
FR2741876B1 (fr) * 1995-12-01 1998-01-09 Cird Galderma Composes biaromatiques portant un groupement adamantyl en para, compositions pharmaceutiques et cosmetiques les contenant et utilisations
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
US6228868B1 (en) 1998-07-27 2001-05-08 Abbott Laboratories Oxazoline antiproliferative agents
WO2000037464A2 (en) * 1998-12-18 2000-06-29 Basilea Pharmaceutica Ag 4-(aminoalkoxy)benzofurans as n-myristoyltransferase inhibitors
CA2393027A1 (en) * 1999-12-17 2001-06-21 Abbott Laboratories Inhibitors of interleukin 5 gene expression
JP4612990B2 (ja) * 2001-03-16 2011-01-12 アボット・ラボラトリーズ ヒスタミン−３受容体リガンドとしての新規アミンおよびそれらの治療的適用
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
TW200304375A (en) 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
US6951880B2 (en) * 2002-05-16 2005-10-04 Genelabs Technologies, Inc. Aryl and heteroaryl compounds as antibacterial and antifungal agents
BR0317430A (pt) * 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
DK1602660T3 (da) * 2003-02-18 2011-05-23 Kyorin Seiyaku Kk Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer
AU2004240649A1 (en) * 2003-05-19 2004-12-02 Irm, Llc Immunosuppressant compounds and compositions
AU2004268455B2 (en) * 2003-08-29 2009-12-17 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
WO2005032471A2 (en) 2003-10-03 2005-04-14 Merck & Co., Inc. Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
TW200538433A (en) * 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
BRPI0512252A (pt) * 2004-06-18 2008-02-19 Biolipox Ab composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
US20060223866A1 (en) * 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
WO2006022442A1 (ja) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
EP1836182A2 (en) 2004-11-18 2007-09-26 The Institutes for Pharmaceutical Discovery, LLC Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
WO2006106711A1 (ja) * 2005-03-30 2006-10-12 Eisai R & D Management Co., Ltd. ピリジン誘導体を含有する抗真菌剤
WO2006115188A1 (ja) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited ヘテロ環化合物
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
CN101291908A (zh) * 2005-08-23 2008-10-22 Irm责任有限公司 免疫抑制剂化合物和组合物
JP2007169194A (ja) 2005-12-21 2007-07-05 Kyorin Pharmaceut Co Ltd ジオキサフォスフォリナン誘導体とその付加塩及びスフィンゴシン−１−リン酸（ｓ１ｐ１，ｓ１ｐ４）受容体作動薬
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
WO2007076348A2 (en) 2005-12-23 2007-07-05 Smithkline Beecham Corporation Azaindole inhibitors of aurora kinases
WO2007092638A1 (en) 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
EP2003132B1 (en) * 2006-04-03 2014-03-05 Astellas Pharma Inc. Oxadiazole derivatives as S1P1 agonists
AU2007243466B2 (en) 2006-04-26 2012-01-19 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
TW200823182A (en) * 2006-08-01 2008-06-01 Praecis Pharm Inc Chemical compounds
BRPI0715950A2 (pt) 2006-08-17 2013-07-30 Univ Chicago tratamento de doenÇas inflamatàrias
JP2009269819A (ja) * 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
JP2010510250A (ja) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−燐酸受容体アゴニスト活性を有するヒドリンダンアナログ
PE20081679A1 (es) 2006-12-07 2008-12-18 Hoffmann La Roche Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
CA2671845C (en) * 2006-12-07 2015-03-24 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
BRPI0720478A2 (pt) 2006-12-21 2014-01-14 Abbott Laboratoires Compostos agonistas e antagonistas do receptor esfingosina-1-fosfato
WO2008099781A1 (ja) 2007-02-13 2008-08-21 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
EP2014653A1 (en) 2007-06-15 2009-01-14 Bioprojet Novel dicarboxylic acid derivatives as S1P1 receptor agonists
US20090118349A1 (en) 2007-08-16 2009-05-07 Onco-Pharmakon Incorporated Bis-alkylating agents and their use in cancer therapy
EP2297139A1 (en) * 2008-06-20 2011-03-23 Glaxo Group Limited Compounds
CN102186845B (zh) 2008-10-17 2016-09-07 阿卡制药有限公司 S1p受体调节剂以及它们的用途
CA2739901A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
US20100160369A1 (en) 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using
US8741923B2 (en) 2008-12-18 2014-06-03 Merck Serono Sa Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
WO2014063199A1 (en) * 2012-10-26 2014-05-01 Akaal Pharma Pty Ltd Organic compounds

Similar Documents

Publication Publication Date Title
ES2660831T3 (es) Derivados de imidazol condensados útiles como inhibidores de IDO
JP2013508279A5 (enExample)
JP2019526596A5 (enExample)
NZ592748A (en) 2-Amino-(oxadiazol-3-yl)-benzofuran derivatives and their use as S1P receptor modulators
JP2010523522A5 (enExample)
JP2010138190A5 (enExample)
JP2014505107A5 (enExample)
JP2012525393A5 (enExample)
JP2015505296A5 (enExample)
JP2008514732A5 (enExample)
JP2014511892A5 (enExample)
JP2013545730A5 (enExample)
JP2017537158A5 (enExample)
JP2009504763A5 (enExample)
RU2017105470A (ru) Способы лечения парамиксовирусов
JP2019520344A5 (enExample)
JP2017531038A5 (enExample)
JP2010501584A5 (enExample)
JP2016040288A5 (enExample)
JP2008539268A5 (enExample)
JP2014505096A5 (enExample)
JP2014500265A5 (enExample)
JP2020505354A5 (enExample)
JP2007520452A5 (enExample)
JP2015516427A5 (enExample)